IL298542B2 - Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts - Google Patents
Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their saltsInfo
- Publication number
- IL298542B2 IL298542B2 IL298542A IL29854222A IL298542B2 IL 298542 B2 IL298542 B2 IL 298542B2 IL 298542 A IL298542 A IL 298542A IL 29854222 A IL29854222 A IL 29854222A IL 298542 B2 IL298542 B2 IL 298542B2
- Authority
- IL
- Israel
- Prior art keywords
- dimethyltryptamine
- solid dosage
- dosage form
- compounds
- disorder
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- C07D209/16—Tryptamines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB2008303.6A GB2585978B (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions |
| US16/890,664 US11771681B2 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compounds |
| PCT/EP2020/065244 WO2020245133A1 (en) | 2019-06-03 | 2020-06-02 | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US17/108,938 US20220169606A1 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| GBGB2018950.2A GB202018950D0 (en) | 2020-12-01 | 2020-12-01 | Parenteral formulation |
| GBGB2018955.1A GB202018955D0 (en) | 2020-12-01 | 2020-12-01 | Compositions and compounds for bioanalysis |
| US17/108,679 US20220168274A1 (en) | 2020-12-01 | 2020-12-01 | Parenteral Formulation |
| GB2103981.3A GB2605144A (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| US17/208,583 US11773062B2 (en) | 2021-03-22 | 2021-03-22 | Deuterated compounds |
| PCT/EP2021/060750 WO2021116503A2 (en) | 2020-06-02 | 2021-04-23 | Deuterated compounds |
| PCT/EP2021/062794 WO2021244831A1 (en) | 2020-06-02 | 2021-05-13 | Therapeutic solid dosage forms |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL298542A IL298542A (en) | 2023-01-01 |
| IL298542B1 IL298542B1 (en) | 2024-10-01 |
| IL298542B2 true IL298542B2 (en) | 2025-02-01 |
Family
ID=76329655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL298542A IL298542B2 (en) | 2020-06-02 | 2021-05-13 | Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts |
Country Status (8)
| Country | Link |
|---|---|
| EP (3) | EP3902541B1 (https=) |
| JP (1) | JP7579888B2 (https=) |
| CN (1) | CN115996713A (https=) |
| AU (1) | AU2021284861A1 (https=) |
| CA (1) | CA3118556A1 (https=) |
| GB (1) | GB2595776B (https=) |
| IL (1) | IL298542B2 (https=) |
| WO (2) | WO2021116503A2 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| JP7422473B2 (ja) | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
| MX2022009528A (es) | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
| PH12022551981A1 (en) | 2020-02-04 | 2023-10-16 | Mindset Pharma Inc | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
| AU2021268204A1 (en) | 2020-05-08 | 2022-12-08 | Psilera Inc. | Novel compositions of matter and pharmaceutical compositions |
| KR20240096817A (ko) | 2020-05-19 | 2024-06-26 | 사이빈 아이알엘 리미티드 | 중수소화된 트립타민 유도체 및 사용 방법 |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| CA3146880C (en) * | 2020-07-29 | 2023-07-18 | Gregory Ellis | Delivery system for ayahuasca-like substances |
| US12122741B2 (en) | 2020-08-18 | 2024-10-22 | Cybin Irl Limited | Therapeutic phenethylamine compositions and methods of use |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| WO2022117640A1 (en) | 2020-12-01 | 2022-06-09 | Small Pharma Ltd | Inhalable formulations |
| IL303288A (en) * | 2020-12-01 | 2023-07-01 | Small Pharma Ltd | N,N-Dimethyltryptamine compounds partially or fully deuterated |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| IL308816A (en) | 2021-05-25 | 2024-01-01 | Atai Therapeutics Inc | New n,n-dimethyltryptamine salts and crystalline salt forms |
| MX2023014620A (es) | 2021-06-09 | 2024-01-30 | Atai Therapeutics Inc | Nuevos profarmacos y conjugados de dimetiltriptamina. |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| EP4159201A1 (en) | 2021-09-30 | 2023-04-05 | Biomind Labs Inc | Encapsulated microparticles and nanoparticles of dimethyltriptamines |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| MX2024005955A (es) | 2021-11-18 | 2024-06-11 | Cybin Uk Ltd | Formulaciones inyectables e inhalables. |
| JP2024545787A (ja) * | 2021-12-30 | 2024-12-11 | アタイ セラピューティクス， インコーポレイテッド | 一酸化窒素送達剤としてのジメチルトリプタミン類似体 |
| US20250051279A1 (en) * | 2022-01-14 | 2025-02-13 | Cybin Irl Limited | Tryptamine compositions and methods |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| AU2023242469A1 (en) * | 2022-03-31 | 2024-09-05 | Cybin Irl Limited | Combination of nitrous oxide and 5-ht2a receptor agonists |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| EP4618981A1 (en) | 2022-11-17 | 2025-09-24 | Remedi, Inc. | Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2020245133A1 (en) * | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20010356A1 (it) | 2001-06-21 | 2002-12-23 | Sigma Tau Ind Farmaceuti | "5-alogeno derivati della triptamina utili come ligandi del recettore5-ht6 e/o 5-ht7 della serotonina. |
| JP6367545B2 (ja) | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| JP7422473B2 (ja) * | 2019-11-07 | 2024-01-26 | サイビン ユーケー リミテッド | 合成方法 |
-
2021
- 2021-04-23 EP EP21720509.5A patent/EP3902541B1/en active Active
- 2021-04-23 WO PCT/EP2021/060750 patent/WO2021116503A2/en not_active Ceased
- 2021-05-13 WO PCT/EP2021/062794 patent/WO2021244831A1/en not_active Ceased
- 2021-05-13 AU AU2021284861A patent/AU2021284861A1/en active Pending
- 2021-05-13 CN CN202180046533.1A patent/CN115996713A/zh active Pending
- 2021-05-13 EP EP21725377.2A patent/EP4149460B8/en active Active
- 2021-05-13 CA CA3118556A patent/CA3118556A1/en active Pending
- 2021-05-13 EP EP24215587.7A patent/EP4494703A3/en active Pending
- 2021-05-13 GB GB2106881.2A patent/GB2595776B/en active Active
- 2021-05-13 IL IL298542A patent/IL298542B2/en unknown
- 2021-05-13 JP JP2022574098A patent/JP7579888B2/ja active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019081764A1 (en) * | 2017-10-26 | 2019-05-02 | Consejo Superior De Investigaciones Científicas (Csic) | ASSOCIATION PRODUCT FOR THE TREATMENT OF NEUROLOGICAL AND / OR PSYCHIATRIC DISORDERS |
| WO2020245133A1 (en) * | 2019-06-03 | 2020-12-10 | Small Pharma Ltd | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds |
Non-Patent Citations (3)
| Title |
|---|
| BEATON J M ET AL,, A COMPARISON OF THE BEHAVIORAL EFFECTS OF PROTEO- AND DEUTERO-N, N-DIMETHYLTRYPTAMINE, 1 May 1982 (1982-05-01) * |
| MORRIS ET AL.,, INDOLEALKYLAMINE METABOLISM: SYNTHESIS OF DEUTERATED INDOLEALKYLAMINES AS METABOLIC PROBES, 31 December 1993 (1993-12-31) * |
| SIMON D. BRANDT ET AL,, MICROWAVE-ACCELERATED SYNTHESIS OF PSYCHOACTIVE DEUTERATED N , N -DIALKYLATED-[ [ALPHA] , [ALPHA] , [BETA] , [BETA] -D 4 ]-TRYPTAMINES, 1 November 2008 (2008-11-01) * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP4149460B1 (en) | 2024-11-27 |
| WO2021116503A2 (en) | 2021-06-17 |
| CA3118556A1 (en) | 2021-12-02 |
| WO2021116503A3 (en) | 2023-09-28 |
| EP3902541B1 (en) | 2022-09-14 |
| EP4494703A3 (en) | 2025-04-02 |
| EP4494703A2 (en) | 2025-01-22 |
| JP7579888B2 (ja) | 2024-11-08 |
| WO2021244831A1 (en) | 2021-12-09 |
| EP4149460B8 (en) | 2025-01-08 |
| EP4149460A1 (en) | 2023-03-22 |
| GB202106881D0 (en) | 2021-06-30 |
| IL298542A (en) | 2023-01-01 |
| GB2595776B (en) | 2023-05-24 |
| AU2021284861A1 (en) | 2023-01-05 |
| GB2595776A (en) | 2021-12-08 |
| IL298542B1 (en) | 2024-10-01 |
| WO2021116503A8 (en) | 2021-08-12 |
| JP2023527575A (ja) | 2023-06-29 |
| EP3902541A2 (en) | 2021-11-03 |
| EP4149460C0 (en) | 2024-11-27 |
| CN115996713A (zh) | 2023-04-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL298542B2 (en) | Solid dosage forms intended for treatment containing deuterium-containing N,N-dimethyltryptamine compounds and their salts | |
| JP2017203047A (ja) | ノルイボガインのリン酸エステル | |
| EP3436083A1 (en) | Novel compositions and methods | |
| JPWO2021244831A5 (https=) | ||
| CA2339008A1 (en) | Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases | |
| JP2003503450A5 (https=) | ||
| EP0844875B1 (en) | Use of basic l-carnitine and acyl derivatives for lowering ceramide levels | |
| CA2165446C (en) | Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade | |
| TW200410683A (en) | Medicament for preventing and/or treating peripheral neuropathies | |
| RU99128026A (ru) | Новая соль | |
| AU2006275824A1 (en) | Method of improving wakefulness | |
| JPH0755906B2 (ja) | ジサツカライド誘導体含有鎮痛剤 | |
| IL298541B2 (en) | 1,1-dideuterio-2-(1H-indol-3-yl)-N,N-bis(trideuteriomethyl)ethanamine and a medical preparation containing it | |
| NZ794813B2 (en) | Therapeutic solid dosage forms | |
| NZ794813A (en) | Therapeutic solid dosage forms | |
| EP0429676B1 (en) | Drug for improving brain function | |
| CN116685316A (zh) | 用于治疗脂质相关失调的组合物和方法 | |
| JP2010526073A (ja) | 癌または前癌性症状およびその他の症状の治療のためのジヒドロピリジン誘導体 | |
| Ban | Haloperidol and the butyrophenones | |
| Hoffman et al. | Cerebrovascular and cerebral metabolic effects of clurazepam and a benzodiazepine antagonist, 3-hydroxymethyl-β-carboline | |
| NZ783166A (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| NZ783166B2 (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| Bersanova et al. | Pharmacokinetics of Amikacin in Eye Media Using Various Drugs | |
| NZ794833B2 (en) | Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds | |
| EP0460358B1 (en) | Agent for treating disorders from cerebral neuro-degeneration |